When autoimmune hepatitis (AIH) occurs in the setting of established cirrhosis, treatment decisions require careful adaptation. The presence of cirrhosis — and critically, whether it is compensated or decompensated — directly determines which immunosuppressive strategies are safe and appropriate.

Clinical Scenario

This protocol addresses autoimmune hepatitis with concurrent cirrhosis of the liver. Certain agents routinely used in AIH are specifically contraindicated in the cirrhotic population, making agent selection a key decision point. The protocol distinguishes between compensated and decompensated presentations.

Treatment Approach — Partial Overview

Management is corticosteroid-based. Whether a second immunosuppressive agent is added — and which patients qualify — depends on the degree of hepatic compensation. A specific corticosteroid formulation commonly used elsewhere in AIH is excluded in this setting due to the pharmacokinetic consequences of portosystemic shunting. The complete regimen, agent selection criteria, and tapering strategy are in the full protocol.

Treatment Goals

The target is biochemical remission: normalization of serum ALT, AST, and IgG levels. Improvement in serum aminotransferase levels within the first two weeks is the key early indicator of adequate response.

References

DOI: 10.1002/hep.31065

For children and adults with AIH who have cirrhosis or who present with acute severe AIH, the AASLD suggests that budesonide not be used (conditional recommendation, very low certainty).
Patients with cirrhosis should not receive budesonide because portosystemic shunting may reduce drug efficacy and promote SSSE by allowing budesonide to bypass the liver.
The ideal laboratory response is normalization of serum ALT, AST, and IgG levels.
The rapidity of response to treatment is the most important index of outcome, and the serum aminotransferase levels should improve within 2 weeks.

View source ↗

Treatment of Autoimmune Hepatitis in Patients with Cirrhosis of the Liver

References